TICKERNERD
Menu
SLSSLSHealthcare · Biotechnology

SLS Stock Forecast: SELLAS Life Sciences Group, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$9.14
+3.04% on the day

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. hold a median 12-month price target of $33 — +255.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 4 Nov 2026 — in the upper half.

Market cap
$1.8B
Ticker Nerd rank
58/ 100
Median analyst target
$33
Analysts covering
2
Revenue$0.0
Operating income−$10.6M
Net income−$9.6M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−11.9%
1M
−22.1%
YTD
+142.4%
1Y
+450.6%
From 52W high
−40.9%
From 52W low
+557.6%
$1
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SELLAS Life Sciences Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
92
Momentum
90
Quality
78
Revisions
61
Size
36
Volatility
35
Growth
34
Accruals
29
Issuance
27

Value (92): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (27): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SLSHigh $35Median $33Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $30Median $33High $35

The green dot is the last close — the median target sits +255.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Mar 2026Maxim GroupMaintainsBuy$7.00 → $10
12 Mar 2026Maxim GroupMaintainsBuy—
16 July 2025Maxim GroupMaintainsBuy—
22 Nov 2023Cantor FitzgeraldReiteratesOverweight—
7 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Nov 2022Alliance Global PartnersMaintainsBuy—
28 June 2022Cantor FitzgeraldMaintainsOverweight—
21 July 2021Cantor FitzgeraldInitiatesOverweight—
18 Nov 2019Alliance Global PartnersInitiatesBuy—
18 Nov 2019H.C. WainwrightInitiatesBuy—
18 Nov 2019Maxim GroupUpgradeBuy—
18 Nov 2019OppenheimerInitiatesOutperform—
15 Nov 2019Maxim GroupUpgradeBuy—
8 Apr 2019Alliance Global PartnersInitiatesBuy—
1 Nov 2018OppenheimerInitiatesOutperform—
20 July 2018Maxim GroupMaintainsBuy—
2 Apr 2018H.C. WainwrightInitiatesBuy—
2 Apr 2018HC Wainwright & Co.InitiatesBuy—
19 Mar 2018Maxim GroupUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SLS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SLS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, SELLAS Life Sciences Group, Inc. returned +450.6% against +14.8% for the S&P 500, dividends included.

SLS vs S&P 500, last 12 monthsTotal return, rebased to 100
02004006008001,000Jan 26Apr 26Jul 26Oct 26SLSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

SELLAS Life Sciences Group, Inc. (SLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−35.5×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
13.0×

Cheaper than 7% of US stocks

EV / EBITDA
−58.5×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−39.6%

Higher than 24% of US stocks

Return on assets
−23.3%

Higher than 17% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SELLAS Life Sciences Group, Inc. (SLS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SELLAS Life Sciences Group, Inc. has a market value of $1.8B and an enterprise value of $1.7B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$32.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$28.4M.

  • Shares outstanding: 201.9M.

  • Trailing P/E: −35.5×; forward P/E: −88.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • SELLAS Life Sciences Group, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

SLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SLSSELLAS Life Sciences Group, Inc.$1.8B58
MAZEMaze Therapeutics, Inc.$1.8B31
AGIOAgios Pharmaceuticals, Inc.$1.9B65
BRVEBraveheart Bio, Inc.$1.8B1
PGENPrecigen, Inc.$1.8B77
GENBGenerate Biomedicines, Inc.$1.8B1
ZBIOZenas BioPharma, Inc.$1.8B20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SELLAS Life Sciences Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SLS news & analysis

SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026

GlobeNewsWire · 4 Nov 2026positive

SELLAS said it will present completed Phase 2 data at the 2026 ASH meeting for SLS009 combined with azacitidine and venetoclax in patients with relapsed or refractory AML after prior venetoclax-based therapy. The company reported ORRs of 54% in relapsed/refractory monocytic AML and 57% in TP53-mutated AML, median overall survival of 5.8 and 8.8 months, respectively, and no meaningful added toxicity.

Why it matters — The presentation will provide further detail on response, survival and tolerability findings for SLS009 in high-risk AML settings with limited historical outcomes.

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

GlobeNewsWire · 25 Sept 2026positive

SELLAS Life Sciences announced preclinical data from studies evaluating its CDK9 inhibitor SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma. The findings are being presented at the AACR Conference on Pancreatic Cancer in San Diego, September 25–28, 2026.

Why it matters — The new preclinical findings could indicate broader potential for SLS009 beyond its currently studied indications, expanding its pipeline opportunity in pancreatic cancer.

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

GlobeNewsWire · 2 Sept 2026positive

SELLAS Life Sciences announced that three abstracts evaluating SLS009 (tambiciclib), a selective CDK9 inhibitor, in preclinical models of pancreatic ductal adenocarcinoma (PDAC) have been accepted for poster presentation at the 2026 AACR Conference on Pancreatic Cancer. The studies were conducted in collaboration with the University of Wisconsin School of Medicine and Public Health and will highlight preclinical activity across patient-derived KRAS mutant organoid models.

Why it matters — For SLS watchers, this expands the potential application of SLS009 beyond its current focus and signals progress in preclinical research for pancreatic cancer, a difficult-to-treat indication.

FAQ

Frequently asked questions about SLS stock

What is the SLS stock price forecast for 2026-2027?

The 2 Wall Street analysts covering SELLAS Life Sciences Group, Inc. have a median 12-month price target of $33, with estimates ranging from $30 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SLS stock a buy right now?

Of the 2 analysts covering SELLAS Life Sciences Group, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SELLAS Life Sciences Group, Inc. 58 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SLS?

As at 4 Nov 2026, SELLAS Life Sciences Group, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (92 of 100).

Will SLS stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +255.6% from the last close, and Ticker Nerd's factor model ranks SELLAS Life Sciences Group, Inc. 58 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SLS stock forecast for 2030?

No analyst covering SELLAS Life Sciences Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $35 over the next 12 months.

How has SLS stock performed over the past year?

SELLAS Life Sciences Group, Inc. returned +450.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SELLAS Life Sciences Group, Inc. do?

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer.

What is the latest news on SLS?

The most recent item we track (GlobeNewsWire, 4 Nov 2026): "SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026". SELLAS said it will present completed Phase 2 data at the 2026 ASH meeting for SLS009 combined with azacitidine and venetoclax in patients with relapsed or refractory AML after prior venetoclax-based therapy. The company reported ORRs of 54% in relapsed/refractory monocytic AML and 57% in TP53-mutated AML, median overall survival of 5.8 and 8.8 months, respectively, and no meaningful added toxicity.

Company

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. Its principal product candidate, galinpepimut-S, is an immunotherapeutic designed to stimulate immune responses against Wilms tumor 1, a protein expressed across multiple tumor types. The company also develops SLS009, a selective cyclin-dependent kinase 9 inhibitor intended to address oncology applications through a distinct molecular mechanism. SELLAS concentrates on late-stage clinical development and therapeutic innovation in areas of significant unmet medical need, serving the pharmaceutical and biotechnology markets. Its work spans cancer immunotherapy, targeted drug development, clinical research, regulatory activities, and potential commercialization of oncology products. Headquartered in New York City, SELLAS occupies a specialized role within the life sciences sector by advancing investigational treatments designed to complement existing cancer-care approaches and broaden the range of therapeutic options available to patients and healthcare providers.

CEO Dr. Angelos M. Stergiou M.D., ScD h.c. · 13 employees · United States · https://sellaslifesciences.com